| Index | — | P/E | 27.11 | EPS (ttm) | 6.72 | Insider Own | 3.05% | Shs Outstand | 58.34M | Perf Week | 7.50% |
| Market Cap | 10.63B | Forward P/E | 20.93 | EPS next Y | 8.70 | Insider Trans | -0.09% | Shs Float | 56.24M | Perf Month | 5.39% |
| Enterprise Value | 12.41B | PEG | 2.75 | EPS next Q | 2.15 | Short Float | 2.48% | Perf Quarter | 1.99% | ||
| Income | 399.00M | P/S | 1.87 | EPS this Y | 21.65% | Short Ratio | 3.89 | Perf Half Y | 3.56% | ||
| Sales | 5.67B | P/B | 4.15 | EPS next Y | 9.73% | ROA | 6.65% | Short Interest | 1.39M | Perf YTD | 4.60% |
| Book/sh | 43.93 | P/C | 27.12 | EPS next 5Y | 9.86% | ROE | 16.63% | 52W High | 218.00 -16.42% | Perf Year | 1.17% |
| Cash/sh | 6.72 | P/FCF | 20.84 | EPS past 3/5Y | 13.92% 13.80% | ROIC | 7.40% | 52W Low | 141.58 28.70% | Perf 3Y | 87.27% |
| Dividend Est. | 0.26 (0.14%) | EV/EBITDA | 18.77 | Sales past 3/5Y | 18.69% 16.05% | Gross Margin | 14.73% | Volatility | 3.92% 2.65% | Perf 5Y | 159.12% |
| Dividend TTM | 0.26 (0.14%) | EV/Sales | 2.19 | EPS Y/Y TTM | 20.21% | Oper. Margin | 8.97% | ATR (14) | 5.37 | Perf 10Y | 903.91% |
| Dividend Ex-Date | Sep 30, 2026 | Quick Ratio | 1.20 | Sales Y/Y TTM | 17.50% | Profit Margin | 7.03% | RSI (14) | 56.17 | Recom | 2.46 |
| Dividend Gr. 3/5Y | 4.31% 4.51% | Current Ratio | 1.20 | EPS Q/Q | 23.78% | SMA20 | 3.34% | Beta | 0.65 | Target Price | 223.25 |
| Payout | 3.75% | Debt/Eq | 0.85 | Sales Q/Q | 14.51% | SMA50 | 4.22% | Rel Volume | 1.74 | Prev Close | 179.06 |
| Employees | 46,000 | LT Debt/Eq | 0.84 | Earnings | Feb 03 | SMA200 | 0.32% | Avg Volume | 353.46K | Price | 182.21 |
| IPO Date | Nov 09, 2007 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 3.09% -1.45% | Net Debt/EBITDA | 2.69 | Volume | 613,892 | Change | 1.76% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-29-26 | Reiterated | UBS | Buy | $230 → $240 |
| Oct-29-26 | Reiterated | Truist Securities | Hold | $202 → $210 |
| Oct-29-26 | Reiterated | Oppenheimer | Outperform | $165 → $215 |
| Jul-28-26 | Reiterated | RBC Capital | Outperform | $222 → $228 |
| Jul-14-26 | Reiterated | Truist Securities | Hold | $215 → $202 |
| Feb-09-26 | Reiterated | RBC Capital | Outperform | $206 → $222 |
| Feb-06-26 | Reiterated | UBS | Buy | $220 → $230 |
| Feb-06-26 | Reiterated | Truist Securities | Hold | $200 → $215 |
| Nov-14-25 | Reiterated | RBC Capital | Outperform | $167 → $206 |
| Nov-10-25 | Reiterated | Truist Securities | Hold | $190 → $200 |
The Ensign Group, Inc. operates as a healthcare provider, primarily concentrating on post-acute care services, alongside other supporting business ventures. The company's activities are organized into two main divisions: Skilled Services and Real Estate. Within its Skilled Services segment, Ensign provides extensive short-term and long-term nursing care tailored for patients recovering from extended illnesses, managing chronic health conditions, or requiring elder care. This division also encompasses a variety of rehabilitative therapies, such as physical, occupational, and speech therapy, among other specialized healthcare provisions. Beyond direct medical care, the company furnishes essential amenities like lodging, customized dietary programs, and opportunities for social engagement, recreation, and entertainment. Ensign additionally manages senior living facilities and delivers convenient mobile diagnostic services. Its diverse array of supplementary services includes digital X-rays, ultrasounds, electrocardiograms, laboratory analyses, sub-acute care, and patient transportation, which can be provided either in patients' residences or at long-term care facilities. The company also engages in the leasing of real estate properties. As of April 4, 2022, Ensign operated a network of 252 healthcare facilities spread across thirteen U.S. states: Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington, and Wisconsin. The Ensign Group, Inc. was established in 1999 and is headquartered in San Juan Capistrano, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 5,674 | 5,058 | 4,260 | 3,729 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 4,839 | 4,258 | 3,593 | 3,139 | — | — | — | — | — | |
| Gross Profit | 836 | 799 | 668 | 591 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 311 | 270 | 225 | 263 | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Other Operating Expense | 15 | 104 | 84 | 72 | — | — | — | — | — | |
| Operating Income | 510 | 425 | 358 | 255 | — | — | — | — | — | |
| Interest Expense | 8 | 8 | 8 | 8 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 31 | 38 | 36 | 25 | — | — | — | — | — | |
| Net Income Before Taxes | 533 | 456 | 386 | 273 | — | — | — | — | — | |
| Income Taxes | 134 | 111 | 88 | 63 | — | — | — | — | — | |
| Consolidated Net Income | 399 | 344 | 298 | 209 | — | — | — | — | — | |
| Net Income From Continuing Operations | 400 | 344 | 298 | 210 | — | — | — | — | — | |
| Net Income | 399 | 344 | 298 | 209 | — | — | — | — | — | |
| EPS (Recurring) | 6.91 | 6.00 | 5.26 | 3.76 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 6.91 | 6.00 | 5.26 | 3.76 | — | — | — | — | — | |
| EPS (Diluted) | 6.72 | 5.84 | 5.12 | 3.65 | — | — | — | — | — | |
| EBITDA | 661 | 568 | 479 | 353 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 27.11 | 29.83 | 25.95 | 30.74 | — | — | — | — | — | |
| Price To Sales Ratio | 1.86 | 1.96 | 1.78 | 1.69 | — | — | — | — | — | |
| Gross Margin | 14.73 | 15.80 | 15.68 | 15.85 | — | — | — | — | — | |
| Operating Margin | 8.99 | 8.40 | 8.40 | 6.84 | — | — | — | — | — | |
| Net Margin | 7.03 | 6.80 | 7.00 | 5.60 | — | — | — | — | — | |
| Shares Outstanding | 58 | 57 | 57 | 56 | — | — | — | — | — | |
| Market Capitalization | 10,568 | 9,929 | 7,573 | 6,284 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Parkinson Mark Vincent | Director | Oct 16 '26 | Sale | 179.62 | 100 | 17,962 | 4,400 | Oct 19 |
| Blouin Ann Scott | Director | Jul 27 '26 | Sale | 183.54 | 375 | 68,829 | 23,677 | Jul 29 |
| Agwunobi John O | Director | Jul 20 '26 | Sale | 171.06 | 392 | 67,056 | 9,503 | Jul 22 |
| Parkinson Mark Vincent | Director | Jul 16 '26 | Sale | 168.12 | 100 | 16,812 | 3,900 | Jul 17 |
| SMITH BARRY M | Director | Jun 02 '26 | Sale | 164.28 | 700 | 114,996 | 21,352 | Jun 04 |
| SMITH BARRY M | Director | May 04 '26 | Sale | 182.21 | 700 | 127,547 | 22,052 | May 06 |
| Agwunobi John O | Director | Apr 20 '26 | Sale | 199.97 | 392 | 78,388 | 9,295 | Apr 22 |
| Parkinson Mark Vincent | Director | Apr 16 '26 | Sale | 196.60 | 100 | 19,660 | 3,400 | Apr 17 |
| SMITH BARRY M | Director | Apr 02 '26 | Sale | 196.65 | 700 | 137,655 | 22,152 | Apr 06 |
| SMITH BARRY M | Director | Mar 02 '26 | Sale | 213.02 | 700 | 149,114 | 22,852 | Mar 02 |
| Uychiat Pison Marivic | Director | Feb 20 '26 | Sale | 204.92 | 67 | 13,730 | 14,340 | Feb 20 |
| Uychiat Pison Marivic | Director | Feb 19 '26 | Sale | 211.02 | 83 | 17,514 | 14,407 | Feb 20 |
| Wittekind Beverly B. | VP and Chief Legal Officer | Feb 19 '26 | Sale | 210.23 | 500 | 105,115 | 32,779 | Feb 20 |
| Wittekind Beverly B. | VP and Chief Legal Officer | Feb 19 '26 | Option Exercise | 83.64 | 500 | 41,820 | 33,279 | Feb 20 |
| Shaw Daren | Director | Feb 17 '26 | Sale | 213.43 | 1,000 | 213,430 | 23,726 | Feb 19 |